• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝纤维化的消退和肝硬化的演变:简要综述。

Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review.

机构信息

Department of Pathology Indiana University School of Medicine, Indianapolis, IN.

出版信息

Adv Anat Pathol. 2021 Nov 1;28(6):408-414. doi: 10.1097/PAP.0000000000000312.

DOI:10.1097/PAP.0000000000000312
PMID:34326286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8508733/
Abstract

Fibrosis is not a unidirectional, linear process, but a dynamic one resulting from an interplay of fibrogenesis and fibrolysis depending on the extent and severity of a biologic insult, or lack thereof. Regression of fibrosis has been documented best in patients treated with phlebotomies for hemochromatosis, and after successful suppression and eradication of chronic hepatitis B and C infections. This evidence mandates a reconsideration of the term "cirrhosis," which implies an inevitable progression towards liver failure. Furthermore, it also necessitates a staging system that acknowledges the bidirectional nature of evolution of fibrosis, and has the ability to predict if the disease process is progressing or regressing. The Beijing classification attempts to fill this gap in contemporary practice. It is based on microscopic features termed "the hepatic repair complex," defined originally by Wanless and colleagues. The elements of the hepatic repair complex represent the 3 processes of fragmentation and regression of scar, vascular remodeling (resolution), and parenchymal regeneration. However, regression of fibrosis does not imply resolution of cirrhosis, which is more than just a stage of fibrosis. So far, there is little to no evidence to suggest that large regions of parenchymal extinction can be repopulated by regenerating hepatocytes. Similarly, the vascular lesions of cirrhosis persist, and there is no evidence of complete return to normal microcirculation in cirrhotic livers. In addition, the risk of hepatocellular carcinoma is higher compared with the general population and these patients need continued screening and surveillance.

摘要

纤维化不是一个单向的、线性的过程,而是一个动态的过程,取决于生物损伤的程度和严重程度,由纤维化和纤维溶解的相互作用产生。纤维化的消退在接受放血疗法治疗血色素沉着症的患者以及慢性乙型和丙型肝炎感染成功抑制和消除后得到了最好的证明。这一证据要求重新考虑“肝硬化”一词,因为它暗示着向肝功能衰竭的不可避免进展。此外,还需要一个分期系统来承认纤维化演变的双向性质,并能够预测疾病过程是在进展还是在消退。北京分类试图填补当代实践中的这一空白。它基于最初由 Wanless 及其同事定义的称为“肝修复复合体”的微观特征。肝修复复合体的要素代表了瘢痕的碎裂和消退、血管重塑(消退)和实质再生这 3 个过程。然而,纤维化的消退并不意味着肝硬化的消退,肝硬化不仅仅是纤维化的一个阶段。到目前为止,几乎没有证据表明实质消失的大片区域可以被再生的肝细胞重新填充。同样,肝硬化的血管病变仍然存在,没有证据表明肝硬化肝脏的微循环可以完全恢复正常。此外,与一般人群相比,这些患者患肝细胞癌的风险更高,需要持续的筛查和监测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c90/8508733/cb697a9b6c92/pap-28-408-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c90/8508733/3e1d8ad8281c/pap-28-408-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c90/8508733/cb697a9b6c92/pap-28-408-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c90/8508733/3e1d8ad8281c/pap-28-408-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c90/8508733/cb697a9b6c92/pap-28-408-g002.jpg

相似文献

1
Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review.肝纤维化的消退和肝硬化的演变:简要综述。
Adv Anat Pathol. 2021 Nov 1;28(6):408-414. doi: 10.1097/PAP.0000000000000312.
2
Regression of human cirrhosis: an update, 18 years after the pioneering article by Wanless et al.肝硬化的逆转:在 Wanless 等人的开创性文章发表 18 年后的最新进展
Virchows Arch. 2018 Jul;473(1):15-22. doi: 10.1007/s00428-018-2340-2. Epub 2018 Mar 27.
3
A review of liver fibrosis and cirrhosis regression.肝纤维化与肝硬化逆转综述
J Pathol Transl Med. 2023 Jul;57(4):189-195. doi: 10.4132/jptm.2023.05.24. Epub 2023 Jun 20.
4
Features of fibrosis regression abound in "non-cirrhotic" patients with resected hepatocellular carcinoma.在接受肝切除术的“非肝硬化”肝细胞癌患者中,纤维化消退的特征比比皆是。
PLoS One. 2022 May 12;17(5):e0267474. doi: 10.1371/journal.pone.0267474. eCollection 2022.
5
Hepatocellular Carcinoma in Patients Without Cirrhosis: The Fibrosis Stage Distribution, Characteristics and Survival.非肝硬化患者的肝细胞癌:纤维化分期分布、特征和生存情况。
Dig Dis Sci. 2022 Jun;67(6):2677-2687. doi: 10.1007/s10620-021-07048-5. Epub 2021 May 23.
6
Iron and liver fibrosis: Mechanistic and clinical aspects.铁与肝纤维化:机制与临床方面。
World J Gastroenterol. 2019 Feb 7;25(5):521-538. doi: 10.3748/wjg.v25.i5.521.
7
PNPLA3 I148M polymorphism and progressive liver disease.PNPLA3 I148M 多态性与进行性肝病。
World J Gastroenterol. 2013 Nov 7;19(41):6969-78. doi: 10.3748/wjg.v19.i41.6969.
8
Should surveillance for liver cancer be modified in hepatitis C patients after treatment-related cirrhosis regression?在治疗相关的肝硬化消退后,丙型肝炎患者的肝癌监测是否应进行调整?
Liver Int. 2016 Jun;36(6):783-90. doi: 10.1111/liv.13106. Epub 2016 Mar 24.
9
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.丙型肝炎病毒清除后,晚期纤维化患者肝硬化相关并发症的风险。
J Hepatol. 2017 Mar;66(3):485-493. doi: 10.1016/j.jhep.2016.10.017. Epub 2016 Oct 22.
10
Human liver regeneration after major hepatic resection. A study of normal liver and livers with chronic hepatitis and cirrhosis.肝大部切除术后的人类肝脏再生。正常肝脏以及患有慢性肝炎和肝硬化的肝脏的研究。
Ann Surg. 1987 Jul;206(1):30-9. doi: 10.1097/00000658-198707000-00005.

引用本文的文献

1
alleviates liver fibrosis via modulation of purine metabolism and NF-κB signaling pathway: insights from multi-omics analysis.通过调节嘌呤代谢和NF-κB信号通路减轻肝纤维化:多组学分析的见解
Front Pharmacol. 2025 Aug 1;16:1630927. doi: 10.3389/fphar.2025.1630927. eCollection 2025.
2
Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease.肝星状细胞:在健康与疾病中平衡体内稳态、肝脏保护和纤维化形成
Nat Rev Gastroenterol Hepatol. 2025 May 22. doi: 10.1038/s41575-025-01068-6.
3
Role of triggering receptor expressed on myeloid cells 2 in the pathogenesis of non-alcoholic fatty liver disease.

本文引用的文献

1
Inflammatory Mechanisms Underlying Nonalcoholic Steatohepatitis and the Transition to Hepatocellular Carcinoma.非酒精性脂肪性肝炎及其向肝细胞癌转变的炎症机制
Cancers (Basel). 2021 Feb 10;13(4):730. doi: 10.3390/cancers13040730.
2
Regression of portal hypertension: underlying mechanisms and therapeutic strategies.门静脉高压症的逆转:潜在机制和治疗策略。
Hepatol Int. 2021 Feb;15(1):36-50. doi: 10.1007/s12072-021-10135-4. Epub 2021 Feb 5.
3
Current perspectives on the tumor microenvironment in hepatocellular carcinoma.当前对肝癌肿瘤微环境的看法。
髓系细胞触发受体2在非酒精性脂肪性肝病发病机制中的作用
World J Hepatol. 2025 Feb 27;17(2):102328. doi: 10.4254/wjh.v17.i2.102328.
4
Hepatitis C Virus-Core Antigen: Implications in Diagnostic, Treatment Monitoring and Clinical Outcomes.丙型肝炎病毒核心抗原:在诊断、治疗监测及临床结局中的意义
Viruses. 2024 Nov 29;16(12):1863. doi: 10.3390/v16121863.
5
Metabolic dysfunction-associated steatotic liver disease: The question of long-term high-normal alanine aminotransferase as a screening test.代谢相关脂肪性肝病:长期高正常丙氨酸氨基转移酶作为筛查试验的问题。
World J Gastroenterol. 2024 Nov 14;30(42):4576-4582. doi: 10.3748/wjg.v30.i42.4576.
6
Review of the Effects of Antiviral Therapy on Hepatitis B/C-Related Mortality and the Regression of Fibrosis.抗病毒治疗对乙型肝炎/丙型肝炎相关死亡率和纤维化消退影响的综述。
Viruses. 2024 Sep 27;16(10):1531. doi: 10.3390/v16101531.
7
Contemporary Insights into Hepatitis C Virus: A Comprehensive Review.丙型肝炎病毒的当代见解:全面综述
Microorganisms. 2024 May 21;12(6):1035. doi: 10.3390/microorganisms12061035.
8
SGLT-2 inhibitors as novel treatments of multiple organ fibrosis.钠-葡萄糖协同转运蛋白2抑制剂作为多器官纤维化的新型治疗方法。
Heliyon. 2024 Apr 11;10(8):e29486. doi: 10.1016/j.heliyon.2024.e29486. eCollection 2024 Apr 30.
9
KIF18A inactivates hepatic stellate cells and alleviates liver fibrosis through the TTC3/Akt/mTOR pathway.KIF18A 通过 TTC3/Akt/mTOR 通路抑制肝星状细胞活化进而缓解肝纤维化。
Cell Mol Life Sci. 2024 Feb 19;81(1):96. doi: 10.1007/s00018-024-05114-5.
10
A Narrative Review on Non-Cirrohotic Portal Hypertension: Not All Portal Hypertensions Mean Cirrhosis.非肝硬化性门静脉高压症的叙述性综述:并非所有门静脉高压症都意味着肝硬化。
Diagnostics (Basel). 2023 Oct 20;13(20):3263. doi: 10.3390/diagnostics13203263.
Hepatol Int. 2020 Dec;14(6):947-957. doi: 10.1007/s12072-020-10104-3. Epub 2020 Nov 13.
4
Molecular and cellular mechanisms of liver fibrosis and its regression.肝纤维化及其逆转的分子和细胞机制。
Nat Rev Gastroenterol Hepatol. 2021 Mar;18(3):151-166. doi: 10.1038/s41575-020-00372-7. Epub 2020 Oct 30.
5
Oncogenic driver genes and tumor microenvironment determine the type of liver cancer.致癌驱动基因和肿瘤微环境决定肝癌的类型。
Cell Death Dis. 2020 May 4;11(5):313. doi: 10.1038/s41419-020-2509-x.
6
Hypoxia-Driven Immune Escape in the Tumor Microenvironment.肿瘤微环境中的缺氧驱动免疫逃逸。
Cells. 2020 Apr 16;9(4):992. doi: 10.3390/cells9040992.
7
Hepatitis C Virus Enhances the Invasiveness of Hepatocellular Carcinoma via EGFR-Mediated Invadopodia Formation and Activation.丙型肝炎病毒通过 EGFR 介导的侵袭伪足形成和激活增强肝癌细胞的侵袭性。
Cells. 2019 Nov 5;8(11):1395. doi: 10.3390/cells8111395.
8
Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis.降低门静脉压力可改善肝硬化患者(伴或不伴腹水)的预后:一项荟萃分析。
Clin Gastroenterol Hepatol. 2020 Feb;18(2):313-327.e6. doi: 10.1016/j.cgh.2019.05.050. Epub 2019 Jun 5.
9
Lipid Metabolic Reprogramming in Hepatocellular Carcinoma.肝细胞癌中的脂质代谢重编程
Cancers (Basel). 2018 Nov 15;10(11):447. doi: 10.3390/cancers10110447.
10
Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis.转化生长因子-β诱导的肝纤维化和肝癌发生中的细胞可塑性
Front Oncol. 2018 Sep 10;8:357. doi: 10.3389/fonc.2018.00357. eCollection 2018.